# Journal of Medicinal Chemistry

Subscriber access provided by - Access paid by the | UCSB Libraries

# Discovery of an Orally Bioavailable Inhibitor of Defective in Cullin Neddylation 1 (DCN1)-mediated Cullin Neddylation

Jared T. Hammill, Deepak Bhasin, Daniel C. Scott, Jaeki Min, Yizhe Chen, Yan Lu, Lei Yang, Ho Shin Kim, Michele C. Connelly, Courtney Hammill, Gloria Holbrook, Cynthia Jeffries, Bhuvanesh Singh, Brenda A. Schulman, and R. Kiplin Guy

J. Med. Chem., Just Accepted Manuscript • DOI: 10.1021/acs.jmedchem.7b01282 • Publication Date (Web): 16 Mar 2018

Downloaded from http://pubs.acs.org on March 17, 2018

## **Just Accepted**

"Just Accepted" manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides "Just Accepted" as a service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. "Just Accepted" manuscripts appear in full in PDF format accompanied by an HTML abstract. "Just Accepted" manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are citable by the Digital Object Identifier (DOI®). "Just Accepted" is an optional service offered to authors. Therefore, the "Just Accepted" Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the "Just Accepted" Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these "Just Accepted" manuscripts.



is published by the American Chemical Society. 1155 Sixteenth Street N.W., Washington, DC 20036

Published by American Chemical Society. Copyright © American Chemical Society. However, no copyright claim is made to original U.S. Government works, or works produced by employees of any Commonwealth realm Crown government in the course of their duties.

Discovery of an Orally Bioavailable Inhibitor of Defective in Cullin Neddylation 1 (DCN1)-
mediated Cullin Neddylation
Jared T. Hammill <sup>1,6</sup> ; Deepak Bhasin <sup>1</sup> ; Daniel C. Scott <sup>2,3</sup> ; Jaeki Min <sup>1</sup> ; Yizhe Chen <sup>1,6</sup> ; Yan Lu <sup>1</sup> ; Lei
Yang <sup>1</sup> ; Ho Shin Kim <sup>1,6</sup> ; Michele C. Connelly <sup>1</sup> ; Courtney Hammill <sup>1</sup> ; Gloria Holbrook <sup>1</sup> ; Cynthia
Jeffries <sup>1</sup> ; Bhuvanesh Singh <sup>4</sup> ; Brenda A. Schulman <sup>2,3,5</sup> ; R. Kiplin Guy <sup>1,6</sup>
<sup>1</sup> Department of Chemical Biology and Theraputics, St. Jude Children's Research Hospital,
Memphis, Tennessee, 38105 USA
<sup>2</sup> Howard Hughes Medical Institute, St. Jude Children's Research Hospital, Memphis, Tennessee,
38105 USA
<sup>3</sup> Department of Structural Biology, St. Jude Children's Research Hospital, Memphis, Tennessee,
38105 USA
<sup>4</sup> Department of Surgery, Laboratory of Epithelial Cancer Biology, Memorial Sloan Kettering
Cancer Center, New York, New York, 10065 USA
<sup>5</sup> Present address: Department of Molecular Machines and Signaling, Max Planck Institute of
Biochemistry, Martinsried, Germany
<sup>6</sup> Present address: Department of Pharmaceutical Sciences, University of Kentucky, Lexington,
KY 40508
*Correspondence: kip.guy@uky.edu

#### Abstract:

We previously reported the discovery, validation, and structure-activity relationships of a series of piperidinyl ureas that potently inhibit the DCN1-UBE2M interaction. We demonstrated that compound **7** inhibits both the DCN1-UBE2M protein-protein interaction and DCN1-mediated cullin neddylation in biochemical assays and reduces levels of steady-state cullin neddylation in a squamous carcinoma cell line harboring DCN1 amplification. Although compound **7** exhibits good solubility and permeability, it is rapidly metabolized in microsomal models (CL<sub>int</sub> = 170 mL/min/kg). This work lays out the discovery of an orally bioavailable analog, NAcM-OPT (**67**). Compound **67** retains the favorable biochemical and cellular activity of compound **7** but is significantly more stable both *in vitro* and *in vivo*. Compound **67** is orally bioavailable, well tolerated in mice, and currently used to study the effects of acute pharmacologic inhibition of the DCN1-UBE2M interaction on the NEDD8/CUL pathway.

### **Introduction**

Ubiquitin-like protein (UBL) modification pathways have emerged as important targets for oncology drug discovery. Successful examples include clinical proteasome inhibitors (e.g., Bortezomib or Carfilzomib)<sup>2</sup>, E3 inhibitors<sup>3</sup>, and the NEDD8 E1 inhibitor (Pevonedistat)<sup>4-6</sup>. Here we present the discovery of an orally bioavailable small molecule inhibitor of the UBL NEDD8 co-E3 enzyme, defective in cullin neddylation 1 (DCN1). DCN1 is also known as DCUN1D1, DCNL1, or SCCRO (squamous cell carcinoma-related oncogene); we use "DCN1" hereafter. DCN1 is an oncogenic driver gene contained within a recurrent 3q26.3 chromosomal amplification that is common in squamous cell carcinomas (SCC) of the lung, head, and neck.<sup>7-13</sup> *DCN1* amplification is associated with malignant transformation, metastasis, and poorer patient survival rates.<sup>7-13</sup>

DCN1 is part of a hierarchical E1-E2-E3 enzymatic cascade that covalently attaches the UBL NEDD8 to target proteins<sup>14</sup>. The first step of this cascade is the ATP-dependent formation of

Page 3 of 41

#### Journal of Medicinal Chemistry

an E1-NEDD8 thioester intermediate. Next, the NEDD8 is transferred from the E1 to a catalytic Cys on the E2. E3s then join the E2-NEDD8 complex and recruit the target protein. This complex consequently catalyzes the formation of an isopeptide bond connecting NEDD8's C-terminus to the γ-amino group of a lysine side-chain on the target protein. DCN1 is a co-E3 that stimulates the neddylation reaction.<sup>15-16</sup> Cullins, the best-characterized substrates of the NEDD8 pathway, are a family of ubiquitin E3 ligases that are activated by neddylation<sup>17-19</sup>. Cullins serve as the catalytic domain for approximately 300 human multi-protein CUL-RING E3 ligases (CRLs) that regulate ubiquitin (UB) conjugation.<sup>18, 20</sup>

The CRLs control diverse biological processes and their dysfunction is implicated in human diseases, including cancer.<sup>21-23</sup> Thus, drug discovery efforts targeting the CRLs continues to grow.<sup>24-27</sup> One approach to inhibiting CRL activity is to block cullin neddylation.<sup>28-31</sup> Pevonedistat (MLN4924) is the most well characterized inhibitor of the NEDD8 pathway and is currently in phase II clinical trials for the treatment of cancer.<sup>6, 32-33</sup> Pevonedistat is an adenosine sulfamate analogue that covalently inhibits the NEDD8 E1, thus inhibiting all neddylation.<sup>34</sup> The success of Pevonedistat has stimulated discovery of other inhibitors of the neddylation pathway. Virtual screening has yielded both reversible and covalent small molecule inhibitors of the NEDD8 E1.<sup>35-38</sup> Several rhodium(III) complexes also inhibit the NEDD8 E1, offering an alternative to small molecules.<sup>39-40</sup> Recently, an inhibitor of the COP9 signalosome, responsible for de-neddylation of the CRLs, has been reported and also displays anti-tumor activity.<sup>41</sup> We, and others, have recently reported the discovery of inhibitors of DCN1.<sup>42-44</sup>

While complete ablation of neddylation appears to be clinically efficacious,<sup>29</sup> it is also toxic. In an effort to maintain efficacy and reduce toxicity, we sought more specific ways to interrogate the neddylation pathway.<sup>42</sup> DCN1 plays a role in tumor formation, maintenance, and regulation of the neddylation pathway.<sup>7-17, 45-46</sup> Therefore, we sought to develop DCN1 inhibitors that may

Page 4 of 41

offer advantages and/or alternative specificities compared to pan-neddylation or de-neddylation inhibitors.<sup>1, 42-43</sup>

We recently identified a class of piperidinyl ureas that inhibit the DCN1-UBE2M protein-

protein interaction and thereby reduce steady-state neddylation of specific cullins.<sup>42</sup> Subsequent iterative structure-enabled optimization of our high throughput screening hit (compound **2**, Table 1, IC<sub>50</sub> = 7.6  $\mu$ M) yielded compound **7** (IC<sub>50</sub> = 0.060  $\mu$ M)<sup>1</sup> that was 100-fold more potent than our initial hit.<sup>1, 42</sup> Our optimization targeting five sub-pockets within the DCN1-UBE2M binding site is reported in the companion manuscript.<sup>1</sup> The first three sub-pockets are the Ile, N-acetyl, and Leu, named for the UBE2M amino acid side chains that occupy these pockets. The last two sub-pockets are the urea and hinge pockets, named for the moieties from the chemotype that occupy them (Figure 1).<sup>42</sup>

Examination of several X-ray co-crystal structures led us to identify four key drivers of



optimization<sup>1</sup>.

potency. This finding is further exemplified by the **1**:DCN1 X-ray co-structure shown in Figure 1 (PDB:  $6BG5)^1$ . The four potency drivers are: (1) the 4-aminopiperidinyl urea core that positions the hydrophobic alky and aryl ends of the molecule into the lle and hinge pockets; (2) a key H-bond between the urea aryl N-H and the backbone amide of Gln114 in the urea pocket; (3) the induced hinge pocket, which affords tight steric packing of hydrophobic residues around the *m*-CF<sub>3</sub> phenyl ring; and (4) the hydrophobic interactions of the methylbenzodioxole urea substituent

within the Leu pocket (Figure 1).<sup>42</sup> Compound **7** biochemically inhibits the DCN1-UBE2M proteinprotein interaction and cullin neddylation.<sup>1</sup> This compound also suppresses steady-state levels of cullin neddylation in HCC95 cells, a squamous carcinoma (SCC) cell line highly expressing DCN1.<sup>1</sup> However, compound **7** is rapidly metabolized in microsomal and murine models. This report describes our continuing optimization efforts aimed at improving the clearance of compound **7**. Our optimization strategy focused on 1) understanding the physical drivers for bioavailability (SPR); and 2) evaluating metabolic and toxic liabilities associated with the scaffold. This strategy has yielded a potent, orally bioavailable, and significantly more stable chemical probe, NAcM-OPT (**67**)<sup>42</sup>.

#### <u>Results</u>

Given the clear effect of compound **7** in cells<sup>1</sup>, we examined whether this compound possessed appropriate absorption, distribution, metabolism, excretion, and toxicology (ADME/T) characteristics to block DCN1 activity using *in vivo* models. Compound **7** was moderately soluble  $(57 \pm 1.4 \mu M)$  and highly cell permeable  $(1400 \pm 39 \times 10^{-6} \text{ cm/s})^1$ . However, compound **7** was unstable in mouse microsomes (CL<sub>int</sub> = 170 mL/min/kg, Table 1). We tested several structurally similar analogs and found that they were also rapidly metabolized (CL<sub>int</sub> > 150 mL/min/kg, Table 1). The most stable analog was the initial screening hit **2** (CL<sub>int</sub> = 90 mL/min/kg). Therefore, it seems as though the structural modifications made to improve potency also reduced metabolic stability. In particular, the benzyl urea substitution that was critical for potency and specificity due to its interactions within the Leu pocket<sup>1</sup> (Figure 1) appears to increase rates of oxidative metabolism.



No	R <sup>1</sup>	R <sup>2</sup>	t(1/2) (hr)	CLint (mL/min/kg)	No	R <sup>1</sup>	R <sup>2</sup>	t(1/2) (hr)	CLint (mL/min/kg)
1			< 0.1	> 500	6	<u></u> sr		$0.150\pm0.019$	$361\pm45.1$
2	C S S S S S S S S S S S S S S S S S S S	т Н	$0.591 \pm 0.0525$	$91.4\pm8.12$	7	~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~		$0.327\pm0.010$	$165\pm25.9$
3			$0.137\pm0.021$	$394 \pm 55.2$	8			$0.245\pm0.014$	$220\pm12.8$
4	rre <sup>2</sup>		0.170 ± 0.016	$318 \pm 29.6$	9			$0.124\pm0.006$	$434\pm21.1$
5	2 <sup>3</sup> 2 <sup>4</sup>		< 0.1	> 500	10	~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	F <sub>3</sub> C	$0.271\pm0.014$	$199\pm9.99$

Table 1. Rapid metabolism of early lead DCN1-UBE2M inhibitors. Values for the half-life and intrinsic clearance were determined at a concentration of 0.8  $\mu$ M using mouse microsomes and are represented as the means plus or minus standard deviation from three replicates. Compound preparation and potency was previously reported.<sup>1</sup>

In order to ensure that the microsomal models accurately predict *in vivo* clearance and reveal any systemic toxicology exhibited by the series, we tested compound **7** in a single-dose intravenous (IV) pharmacokinetic (PK) study using three doses: 0.5, 1.0, and 1.5 mg/kg (Figure 2A). We did not observe any adverse reactions or compound-related side effects within 48 h after dosing (Supplementary Table 1). Compound **7** was rapidly cleared ( $t_{1/2} = 0.14$  h,  $Cl_{plasma} = 42$  L/h/kg) at all doses, suggesting that the microsomal models correctly predict clearance of compound **7** *in vivo*. Therefore, we sought to mitigate the scaffold's inherent metabolic liabilities using microsomal models as a predictor of *in vivo* clearance.

We utilzed a recursive process of analog design, synthesis, testing, and design refinement to optimize the series. We assessed biochemical potency using our previously reported TR-FRET Page 7 of 41

#### Journal of Medicinal Chemistry

assay,<sup>42</sup> which measures the binding of full-length DCN1 to a constrained peptide corresponding to N-terminally acetylated UBE2M<sup>15-16, 42</sup>. We used structurally directed modifications, as well as more empircal investigation of the moeity fitting into the induced fit hinge pocket to probe the steric and electronic requirements of binding<sup>47-51</sup>. We assessed the metabolic stability of all analogs exhibiting reasonable potency in mouse microsomes. Analogs that retained potency and posessed significantly improved microsomal stability were profiled in murine models to determine *in vivo* toxicity, clearance, and bioavailability.

To further guide the design of metabolically stable analogs, we conducted metabolite identification (Met-ID) studies using a close structural analog of compound **7**, compound **5** (Figure 2B). This study identified N-dealkylation (**11**) of the piperidine ring in the lle targeting substituent and oxidation of the aromatic ring of the urea (**12**), targeting the hinge region, as the primary metabolic transformations (Figure 2B; Supplementary Table 2). Time-course metabolite formation studies suggest that these modifications take place sequentially; oxidation of the aromatic ring occurs first, followed by N-dealkylation (Supplementary Table 2). Although we were unable to identify the specific oxidized carbon on the aromatic ring, we hypothesize that the carbons *ortho*-or *para*- to the amino group are the most likely the sites of oxidation. This hypothesis is based on the electron donating nature of the amino substituent and on previous reports<sup>52-63</sup>. Therefore, we targeted optimization of the lle and hinge moieties. We used both a rational, structure-based, design and an empirical parallel chemistry approach to understand the key structural elements that drive the structure-activity relationship (SAR) and structure-property relationship (SPR) that define metabolic liabilities.



**Figure 2. Characterization of compound metabolism.** A) Compound **7** plasma concentrations over 24 h following IV administration 0.5, 1.0, and 1.5 mg/kg doses. Plasma concentrations from time points taken after 2 h were below the limit of quantitation and are thus excluded from the graph. B) Summary of metabolite identifications studies using compound **5**. For details, see Supplementary Table 2.

Following these findings, we sought to maintain potency and improve metabolic stability by leaving invariant the benzyl group (targeting the Leu pocket) of compound **7** and varying the alkyl side chain (targeting the IIe pocket) and aniline (targeting the hinge pocket) (Figure 1). We devised two synthetic routes that permitted late stage introduction of either substituent (Scheme 1; routes i, ii). Both routes were amenable to parallel synthesis.

Synthesis of aniline analogs began by alkylation of 4-piperidone (**13**) with 2-iodopentane (Scheme 1; routes i)<sup>42</sup> to generate ketone **14**. Reductive amination of **14** with benzylamine furnished the secondary amine **15**<sup>42</sup>. **15** was then either coupled directly with isocyanates or with anilines using cabonyldiimidazole (CDI) as a coupling agent (**21 – 46**, Tables 2 & 3)<sup>54-57</sup>. Given the wider availability of anilines, we used the CDI-mediated reaction for our parallel chemistry. For this reaction, it was critical to allow CDI to react with the aniline prior to addition of the secondary amine **15**. The optimized procedure required no work-up and direct purification by HPLC chromatography afforded moderate yields (30-55%) of the desired products. The scalability

and ease of this synthetic route allowed us to prepare roughly 140 analogs variant in the aniline substituent.

Synthesis of analogs targeting variation of the alkyl sidechain started with reductive amination of 1-*N*-boc-4-piperidone (**16**) with benzylamine to give **17**. A limited range of anilines with electron-withdrawing substitutions provided appropriate activity and the potential for increased stability. Thus, the secondary amine **17** was coupled with 3-fluoro-5-(trifluoromethyl)phenyl isocyanate to give **18**. After BOC de-protection, Lewis acid-mediated reductive amination<sup>58</sup> of **18** with either ketones or aldehydes, afforded the targeted analogs (**47** – **61**, Table 4) in moderate to good yields (40-75%). We used this route to prepare roughly 45 analogs variant in the alkyl side chain (Supplementary Dataset 1). Compounds prepared by parallel synthesis were characterized for purity (≥ 95% as characterized by UV/ELSD) and identity using UPLC-LRMS (Supplementary Dataset 1). Compounds that proved critical to our SAR analysis were further characterized using <sup>1</sup>H NMR and HRMS (Supplementary Information).

Our studies revealed that the *n*-butyl alkyl sidechain was as potent but more metabolically stable than the 2-pentyl substitution (Table 5). Thus, we synthesized a final set of analogs starting from commercially available *n*-butyl piperidinone **19** (Scheme 1; route iii)<sup>42</sup>. This two-step procedure is readily scalable and has been used to prepare more than five grams of our top compound **67** with > 98% purity as characterized by UV/ELSD and NMR analysis<sup>42</sup>.



Scheme 1. General synthetic routes for generating analogs. (a) potassium carbonate, 2iodopentane, acetonitrile, 80 °C, 16 h, 30-48% (b) benzylamine, sodium triacetoxyborohydride, acetic acid, dichloromethane, rt, 16 h, 90-100%; (c) R<sup>1</sup>-isocyanate, N,N-diisopropylethylamine, dichloromethane, rt, 2 h, 40-80%; (d) R<sup>1</sup>-amine, 1,1'-carbonyldiimidazole, tetrahydrofuran, 16 h, 30-55%; (e) 3-Fluoro-5-(trifluoromethyl)phenyl isocyanate, N,N-diisopropylethylamine, dichloromethane, rt, 2 h, 80-99%; (f) trifluoroacetic acid, dichloromethane, 0 °C - rt, 16 h, 95%; (g) R<sup>2</sup> (aldehyde or ketone), dibutyltin (IV) chloride, phenylsilane, tetrahydrofuran, rt, 16 h, 40-75%.

First, we explored the SAR/SPR of the aniline urea substituent targeting the hinge pocket. Our previous SAR studies and X-ray co-structures revealed that to permit deeper compound binding, the hinge pocket undergoes a structural rearrangement to produce a hydrophobic cavity composed of alkyl and aromatic residues (Ile86, Phe89, Val102, Ile105, Ala106, Phe109, Ala111, Phe117, Phe122, Phe164)<sup>1, 42</sup>. Throughout all of our investigations, an aromatic ring with a small hydrophobic substituent proved optimal for filling this sub-pocket. Compound **7** (IC<sub>50</sub> = 0.060  $\mu$ M),

#### Journal of Medicinal Chemistry

the most potent analog, utilizes a *meta*-trifluoromethylphenyl aniline that fits perfectly into the hinge sub-pocket<sup>1</sup>. Previous work suggests that although *meta*- and *para*- substitutions were tolerated, modestly increased steric bulk or *ortho*-substitution eliminate binding<sup>1</sup>. Thus, we used the parallel chemistry route to rapidly produce diverse analogs while paying particular attention to roughly isosteric *para*- and *meta*- substituted aniline rings (Table 2).

Initial exploration of mono-substituted phenyl ureas (Table 2, 21 - 30) revealed that only the *para*-bromo (**26**) and *para*-iodo (**27**) analogs were as potent as compound **7**, with half maximal inhibitory concentrations (IC<sub>50</sub>'s) of roughly 0.060 µM. All of the mono-substituted phenyl ureas were rapidly cleared in the microsomal assay (CL<sub>int</sub> > 120 mL/min/kg). Halogen substituents were generally more potent than the corresponding alkyl substituents, suggesting that while hydrophobicity is necessary, the presence of an electron-withdrawing group, and potentially a hydrogen bond acceptor, is important for potency (**25 – 27**). This result suggested that we pursue the common strategy of decreasing the rate of metabolic oxidation of aromatic rings by decreasing their electron density. Indeed, such analogs were slightly more stable in microsomal models than compound **7** (CL<sub>int</sub> = 170 mL/min/kg vs. between 120 and 160 mL/min/kg, Table 2).

In concordance with previous studies,<sup>1</sup> larger substitutions such as *i*-Pr (**23**, **29**) and *t*-Bu (**30**) significantly reduced analog potency (Table 2, Supplementary Dataset 1). Similar to the *para*series, the *meta*-substituted compounds' potency appeared to improve with hydrophobic electronwithdrawing substituents. The *meta*-trifluoromethylphenyl (**7**, IC<sub>50</sub> = 0.060  $\mu$ M) was more potent than the *meta*-chlorophenyl (**22**, IC<sub>50</sub> = 0.300  $\mu$ M), a result that stands in stark contrast to the *para*-substituted analogs (*p*-CF<sub>3</sub> (**24**) IC<sub>50</sub> = 0.300  $\mu$ M; *p*-Cl (**25**), IC<sub>50</sub> = 0.100  $\mu$ M). The *meta-i*-Pr analog (**23**, IC<sub>50</sub> = 0.350  $\mu$ M) was more potent than the *para-i*-Pr analog (**29**, IC<sub>50</sub> = 0.650  $\mu$ M). The *meta*-fluoro analog (**21**) was less potent (IC<sub>50</sub> = 1.70  $\mu$ M), likely due to its inability to fill the available pocket. Together, these results suggest that the *meta*-position affords slightly more room for increased steric bulk compared to the *para*-position. The results also highlight that subtle variations in size and electronic properties can significantly affect potency when there is induced fit in the binding site. The *para*-iodo analog (**27**,  $IC_{50} = 0.050 \mu$ M) was the only compound that maintained the potency of compound **7** and increased stability ( $CL_{int} = 120 \text{ mL/min/kg}$ ). However, the observed increase in stability ( $CL_{int} = 170 \text{ mL/min/kg}$  vs. 120 mL/min/kg) was not sufficient to render the compound suitable for *in vivo* studies. We next investigated the di-substituted phenyl ureas with the intent to identify a substituent with improved potency and stability.



No	R <sup>4</sup>	IC <sub>50</sub> (μM) (95% CI) <sup>a</sup>	t(1/2) (hr)	CLint' (mL/min/kg)	No	D	R <sup>4</sup>	IC <sub>50</sub> (μM) (95% CI) <sup>a</sup>	t(1/2) (hr)	CLint' (mL/min/kg)
21	-N F	1.69 (0.640 - 4.46)	≤ 0.10	≥ 500	26	6	-N Br	0.068 (0.049 - 0.095)	$0.386\pm0.021$	$148\pm7.63$
22	, N, CI	0.304 (0.239 - 0.386)	≤ 0.10	≥ 500	27	7	-N O	0.054 (0.044 - 0.066)	$0.498\pm0.013$	$115\pm2.78$
23	-N -	0.353 (0.288 - 0.434)	$0.223\pm0.021$	$256\pm22.4$	28	3	H N	0.356 (0.241 - 0.527)	$0.160\pm0.015$	$356\pm31.9$
24	-N -N F	0.314 (0.229 - 0.432)	$0.455\pm0.012$	$125\pm3.17$	29	)	-N N	0.654 (0.445 - 0.961)	0.177 ± 0.003	$323\pm4.46$
25	-N CI	0.112 (0.082 - 0.152)	$0.368\pm0.027$	$156 \pm 10.7$	30	)	H N	1.72 (1.23 - 2.41)	ND	ND

Table 2. Optimization of the phenyl urea occupying the hinge pocket. IC50 values were generated using our TR-FRET binding assay and are represented as the mean of three replicates with errors reported as the 95% confidence interval. <sup>a</sup>95% confidence intervals were generated based on non-linear regression using the R drc package with the four-parameter log-logistic function (LL2.4)<sup>59</sup>. Values for the half-life and intrinsic clearance were determined at a concentration of 0.8  $\mu$ M using mouse microsomes and are represented as the means plus or minus standard deviation from three replicates. ND = data not determined.

The targeted di-substituted phenyl ureas (Table 3) were designed to solidify the trends observed for the mono-substituted analogs. That is, the analogs should incorporate small hydrophobic and electron-withdrawing substituents at either the *ortho*- or *para*- position. These substitutions appear to electronically and sterically block oxidation of the aromatic ring without negatively affecting potency. We first tested *meta*- and *para*- di-substituted analogs (**31 – 35**). These analogs retained moderate potency with the *meta*-nitro, *para*-chloro analog (**31**) exhibiting an IC<sub>50</sub> value below 0.100  $\mu$ M. However, due to the potential toxicology associated with the nitro substituent<sup>60</sup>, this compound was deprioritized. These compounds were also subject to rapid metabolism. The *meta*-trifluoromethyl, *para*-nitrile derivative **34** (IC<sub>50</sub> = 0.260  $\mu$ M) was the only compound that was significantly more stable in the microsomal model than compound **7** (IC<sub>int</sub> = 60 mL/min/kg vs. 120 mL/min/kg). Among the phenyl ureas with bis-*meta* substitution patterns, only the *meta*-trifluoromethyl, *meta*-fluoro analog **36** was equipotent to compound **7** (IC<sub>50</sub> = 0.060  $\mu$ M). The corresponding *meta*-chloro, *meta*-fluoro analog **37** was significantly less potent, further emphasizing the tightly constrained nature of the SAR. All of the bis-*meta* analogs were rapidly metabolized.



Table 3. Second round of optimization of the phenyl urea occupying the hinge pocket. IC50 values were generated using our TR-FRET binding assay and are represented as the mean of three replicates with errors reported as the 95% confidence interval. <sup>a</sup>95% confidence intervals were generated based on non-linear regression using the R drc package with the four-parameter log-logistic function (LL2.4)<sup>59</sup>. Values for the half-life and intrinsic clearance were determined at a concentration of 0.8  $\mu$ M using mouse microsomes and are represented as the means plus or minus standard deviation from three replicates. ND = data not determined.

We next examined *ortho*-, *meta*- di-substituted phenyl ureas. We observed reduced potency even in the presence of small *ortho*- substituents (Table 3, **38 – 41**), which is consistent with previous SAR data<sup>1</sup>. This series led to the emergence of the pyridine analog **41** - our first compound to exhibit good metabolic stability ( $CL_{int} < 13 \text{ mL/min/kg}$ ). Unfortunately, this



Page 15 of 41

compound, like other pyridine-containing analogs, exhibited significantly reduced potency ( $IC_{50} = 13 \mu$ M, Supplementary Dataset 1)<sup>1, 42</sup>. Examination of fused bicyclic aryl ureas revealed a general trend that the hydrophobic carbocyclic compounds were more potent than their heterocyclic counterparts (**42** – **46**). The 2-napthyl analog (**46**) afforded our first significant gain in potency ( $IC_{50} = 0.020 \mu$ M). However, all of the fused bicyclic analogs were rapidly metabolized in the microsomal model (Table 3). This result illustrates a common phenomenon in medicinal chemistry: as one parameter is optimized, another in compromised. Based on these analogs, we hypothesized that reducing the electron density of the aniline ring would mitigate the oxidation of the aromatic ring, but the scope of the SAR would be narrow.

In parallel to our investigations of aniline analogs, we sought to address N-dealkylation of the alkyl-piperidine by exploring various substitutions occupying the lle pocket. Initially, we fixed the aniline substituent as the *meta*-CF<sub>3</sub>, *meta*-F, based on inhibitory potency. Using this base, we screened a range of analogs replacing the 2-pentyl piperidine substitution that targets the lle sub-pocket (Figure 1). Our previous studies closely explored alkyl substituents at this position and revealed that an *n*-butyl group was preferred and branched alkyl chains improved potency<sup>1</sup>. We have also previously prepared simple benzyl and aryl analogs. To expand our SAR, we explored several other alkyl, aryl, and heteroaryl substituents (Table 4, **47** – **61**). Unfortunately, with the exception of the *n*-butyl analog **47** (IC<sub>50</sub> = 0.260  $\mu$ M), all of the substituents led to significantly reduced potency (Table 4, Supplementary Dataset 1). Thus, we selected only compound **47** for further evaluation in the microsomal model.



**Table 4**. **Optimization of the alkyl piperidine.** IC50 values were generated using our TR-FRET binding assay and are represented as the mean of three replicates with errors reported as the 95% confidence interval. <sup>a</sup>95% confidence intervals were generated based on non-linear regression using the R drc package with the four-parameter log-logistic function (LL2.4)<sup>59</sup>.

Microsomal modeling revealed that compound **47** was significantly more stable than compound **7** ( $CL_{int} = 22 \text{ mL/min/kg}$  vs. 170 mL/min/kg), with only a five-fold reduction in biochemical potency ( $IC_{50} = 0.260 \mu \text{M}$  vs. 0.060  $\mu \text{M}$ ). Comparison of **47** to the 2-pentyl derivative **36** revealed that replacing the 2-pentyl substitution with an *n*-butyl substitution markedly increased stability ( $CL_{int} = 22 \text{ mL/min/kg}$  vs. 290 mL/min/kg). Assuming this was a general trend, we examined other aryl ureas containing the *n*-butylpiperidine (Table 5). The di-substituted analogs were more stable than the corresponding mono-substituted aryl urea analogs. The di-substituted *para*-fluoro, *meta*-trifluoromethyl (**70**) or *meta*-fluoro, *meta*-trifluoromethyl (**47**) were more stable than the *ortho*-fluoro, *meta*-trifluoromethyl (**69**). This result supports our hypothesis that the site of oxidation is most likely the carbon *para*- to the amino substituent. Compound **67**, which contains

a *meta*-chloro, *para*-chloro phenyl urea afforded the best balance of potency and stability. Compound **67** (IC<sub>50</sub> = 0.050  $\mu$ M) retains the biochemical potency of our optimized hit compound **7** but is significantly more stable in microsomal models with a calculated intrinsic clearance of 25 mL/min/kg.

simply decreased their rate of formation, we conducted metabolite identification studies with **67** (Supplementary Table 3). These studies revealed that replacing the *meta*-trifluoromethyl group of the aniline with a *meta*-, *para*-dichloro group effectively decreased the rate of microsomal oxidation. However, oxidation of the aniline ring remained a minor metabolic pathway. N-dealkylation was now the predominant metabolism event. Additionally, we observed oxidation of the benzyl urea substituent targeting the Leu pocket. These results indicate that further optimization may yield even more stable compounds. We believed we had successfully increased simulated oxidative stability without negatively affecting potency, and therefore sought to characterize the toxicology and pharmacokinetic characteristics of compound **67** in murine models.



**Table 5. Final optimization of** *n*-butylpiperidines. IC50 values were generated using our TR-FRET binding assay and are represented as the mean of three replicates with errors reported as the 95% confidence interval. <sup>a</sup>95% confidence intervals were generated based on non-linear regression using the R drc package with the four-parameter log-logistic function (LL2.4)<sup>59</sup>. Values for the half-life and intrinsic clearance were determined at a concentration of 0.8  $\mu$ M using mouse microsomes and are represented as the means plus or minus standard deviation from three replicates. ND = data not determined.

We first conducted a low-dose IV PK experiment to understand the gross toxicity and clearance of compound **67** (Figure 3A). Similar to compound **7**, **67** failed to induce any measureable adverse reactions during the 48 h monitoring period following IV administration (Supplementary Table 4, 5). The observed  $C_{max}$  of compound **7** (Figure 2A) and **67** (Figure 3A) shows a non-linear increase from 0.5 to 1.5 mg/kg. Both compounds exhibit similar and large volumes of distribution (87.3 – 176 L/kg). The IV half-life of **67** is 3-4 hours, which is significantly longer than the half-life of compound **7** ( $t_{1/2} = 0.14-0.2$  h). The increased metabolic stability of

compound **67** correlates with the results from the microsomal model, which showed that this compound has a six-fold lower clearance in mouse microsomes (Supplementary Table 6). Due to the comparatively shorter half-life and lower  $C_{max}$ , the AUC<sub>last</sub> of compound **7** is much smaller than that of compound **67**. Therefore, compound **67** is the preferred early lead for preliminary *in vivo* studies. Based on these results, we determined that it was unethical to conduct an oral dosing study for compound **7**. However, we did conduct an oral PK experiment with compound **67** (Figure 3B).



**Figure 3. Preliminary pharmacokinetic profiling of compound 67**. A) Time course of the drug plasma concentration over 24 h resulting from single dose intravenous administration of **67** at doses of 0.5, 1.0, and 1.5 mg/kg. B) Time course of the drug plasma concentration over 24 h resulting from single oral doses of **67** at 50, 100, and 200 mg/kg. C) Repeated dose-exposure studies to determine toxicological responses. Subjects were dosed orally with 200 mg/kg either

once a day (QD) or twice a day (BID) and drug plasma concentration was measured 1 h after drug administration. D) Table comparing the *in vitro* and *in vivo* clearance data. Results support our hypothesis that the microsomal models predict *in vivo* clearance. Additional PK parameters are in Supplementary Table 6.

When dosed orally as a suspension in EtOH/PG/PEG/PBS (10/10/40/39; v/v/v/v; pH = 7.4) and 1% (w/v) 2-hydroxy- $\beta$ -cyclodextrin (MW~1396 Da), compound **67** displayed a half-life of 3-5 h. This observation concurs with the IV half-life of 3-4 h and suggests that 1) the total exposure is driven by clearance and 2) levels of absorption are optimal. The observed C<sub>max</sub> and AUC<sub>last</sub> show a dose-dependent increase from 1.5 to 3  $\mu$ M and 3.4 to 17.1  $\mu$ M\*h, respectively. The apparent volume of distribution and clearance are similar to those of IV. Based on these data, compound **67** has an oral bioavailability of 88% (calculated using IV dose at 1.5 mg/kg and PO dose at 50 mg/kg). This apparent bioavailability (F<sub>in vivo</sub>) is close to what we predicted from *in vitro* clearance (F<sub>in vitro</sub> = 78%), calculated by 1 - CL/Qn<sup>61</sup>. Compound **67** did not cause a significant adverse reaction at any dose tested during the 48 h monitoring period following oral administration (Supplementary Table 7, 8).

In order to enable efficacy modeling in mice, we investigated the toxicology and pharmacokinetics of compound **67** during repeat-dose experiments over a period of 14 days using either once (QD) or twice (BID) daily schedule with a fixed oral dose of 200 mg/kg. Throughout the 14-day dosing period, no adverse reactions or compound-related side effects were observed (Supplementary Table 9, 10). Dosed animals in both groups experienced minor weight loss (3-5%) during the first 3 days, but resumed normal growth within 5 days (Supplementary Figure 1). In order to determine if there were significant changes in metabolism and clearance during the study period, drug plasma concentrations were monitored one hour post administration after each oral dose (Figure 3C). C<sub>1h</sub> was  $2.4 \pm 0.93 \,\mu$ M (QD) and  $3.3 \pm 1.5$  (BID), and was consistent with earlier data from our single oral dose study (C<sub>1h</sub> = 3  $\mu$ M at 200 mg/kg). Therefore, compound **67** 

is well tolerated, possesses good oral bioavailability, and is suitable for use in animal efficacy models.

The details of the biochemical selectivity and cellular activity of compound **67** (NAcM-OPT), along with an irreversible inhibitor (NAcM-COV), and a structurally related negative control (NAcM-NEG), have recently been disclosed.<sup>42</sup> Briefly, compound **67** maintains the high level of selectivity for inhibition of DCN1/2 over the highly homologous remaining human DCN isoforms.<sup>42</sup> Compound **67** effectively disrupts the DCN1-UBE2M interaction and UBE2M interactome in cells.<sup>42</sup> In HCC95, a squamous carcinoma cell line highly expressing DCN1, either treatment with compound **67** or knockdown of DCN1 with shRNA selectively reduces steady-state levels of neddylated CUL1 and CUL3 while CUL2, CUL4A, and CUL5 are relatively unaffected.<sup>42</sup> Compound **67** inhibits steady-state levels of neddylated CUL1 and CUL3 in a dose-dependent manner (Figure 4A). Consistent with our previous studies,<sup>42</sup> treatment of HCC95 cells with compound **67** does not elicit gross substrate stabilization (Figure 4B). However, at longer exposures, which oversaturate MLN4924 treated protein levels making direct comparison no longer possible, compounds **67** elicits a dose-dependent increase in the known CUL1/CUL3 substrates Cylin E or p21 (Supplementary Figure 2).



**Figure 4.** Western blot for inhibition of cellular neddylation and increased levels of substrates at 48 hours by DMSO, MLN4924 (positive control, 1  $\mu$ M, single dose at T = 0), and compound **67** (indicated concentration, dosing at T = 0, and T = 24 hr). A) Dose-dependent inhibition of steady-state levels of CUL1 and CUL3 neddylation. B) Dose-dependent effects of 67 on steady-state levels of NRF2 and p27.

#### **Discussion and Conclusions**

In the present study, we employed both a rational, structure-based, design as well as an empirical chemistry approach to uncover the key structural elements critical for binding to DCN1 and driving compound metabolism. Our studies yielded compound **67**, which is equipotent to earlier leads like compound **7** but is significantly more bioavailable. By developing short, scalable, synthetic routes, we rapidly prepared over 200 analogs (Supplementary Dataset 1) to select compounds with better PK profiles. A combinatory approach of microsomal modeling and *in vivo* PK allowed us to confidently conclude that the microsomal models correctly predict *in vivo* clearance. Metabolite identification studies focused our attention on the most rapidly metabolized moieties of the inhibitor series: the aniline and alkyl side chain of the piperidine. The structure-based design incorporated our previously described X-ray co-structures and SAR data<sup>1, 42</sup> and allowed us to narrow our focus to the substituents that were most likely to yield potent molecules.

Page 23 of 41

#### Journal of Medicinal Chemistry

In total, 38 of the newly synthesized analogs possessed potency values less than or equal to 360 nM in our TR-FRET binding assay (Supplementary Dataset 1). In parallel to the rational design approach, we employed an empirical approach to discover unexpectedly potent analogs, such as the bicyclic compound **45**, which appears to bypass the stringent steric restrictions in the hinge sub-pocket, as suggested by our previous data. In the face of a known induced fit binding event, we believe it is imperative to keep testing the limits of the design model. The ease and scalability of the synthetic routes allowed us to produce ample material for both the PK and extended dosing studies. The synthetic routes will also allow us to produce sufficient quantities for future *in vivo* studies.

We observed two general SAR/SPR trends. First, the incorporation of small hydrophobic and electronegative substituents at either or both of the *meta*- and *para*- positions of the aniline ring electronically and sterically blocked oxidation of the aromatic ring without negatively affecting potency. Second, the SAR of the alkyl piperidine substituent was highly restricted only tolerating small hydrophobic substituents.<sup>1</sup> Subsequent metabolite identification studies using the optimized compound **67** revealed that although incorporating the di-chlorophenyl ring reduced the oxidation of the aniline substituent. N-dealkylation of the 4-aminopiperidine and oxidation of the benzyl urea substituent targeting the Leu pocket were still prevalent. Future synthetic efforts will focus on these regions as well as on accessing the currently unoccupied N-acetyl pocket, which likely affords the best opportunity for potency gains.<sup>16</sup>

We are currently using compound **67** and others to dissect the effects of acute pharmacologic inhibition of the DCN1-UBE2M interaction on the NEDD8/CUL pathway in both cellular and *in vivo* models. The data suggest that inhibiting this NEDD8 E2-E3 interaction has significantly different biological consequences from inhibition of the upstream NEDD8 E1 by Pevonedistat or other E1 inhibitors. Pevonedistat acts by irreversibly inhibiting the E1 enzyme that initiates the NEDD8 tri-enzyme cascade, completely blocking all neddylation. Compound **67** 

selectively reduces the steady-state neddylation of specific cullins. The most striking phenotypic difference is that unlike E1 inhibition, compound 67 does not grossly stabilize canonical Cullin-RING ligase substrates.<sup>42</sup> However, compound **67** does elicit a minor and selective increase in the levels of two known CRL substrates, NRF2 and p27. Compound 67 also inhibits the anchorage-independent growth of HCC95 cells, a phenotypic consequence associated with DCN1-amplification and hallmark of cancer in this squamous cell carcinoma line.<sup>42</sup> Future experiments, outside the scope of this work, will focus on understanding the mechanisms driving the observed selectivity and phenotypic consequences associated with acute DCN inhibition in cells and murine models. These results suggest that selective regulation of the neddylation pathway still influences tumor progression, at least in cells harboring DCN1 amplification. However, we are clear to point out that selective inhibition of the DCN1-UBE2M interaction is not grossly toxic to the proliferation of monolayer cultures. Given the high levels of DCN1 amplification exhibited in many human cancers,7, 11, 13 selective inhibition of DCN1-mediated neddylation could provide a more targeted therapy relative to the complete ablation of neddylation afforded by Pevonedistat or other NEDD8 E1 inhibitors. Recent reports of a second class of DCN1 inhibitors demonstrates a similar spectrum of activity.<sup>43-44</sup>

In conclusion, the development of compound **67** permits a more selective and acute pharmacologic regulation of this highly complex and dynamic pathway that is already helping to discover previously unappreciated biological roles of DCN1-mediated neddylation,<sup>42, 62</sup> and hopefully will provide further insight into tumor biology in areas with significant unmet clinical need.

#### **Experimental Section**

#### TR-FRET Assay<sup>1, 42</sup>

The TR-FRET assay was carried out in black 384-well microtiter plates at a final volume of 20 µL per well. To screen library compounds, the assay cocktail was prepared as a mixture of

50 nM Biotin-DCN1, 20 nM Ac-UBE2M12-AlexaFluor488, 2.5 nM Tb-Streptavidin (ThermoFisher) in assay buffer (25 mM HEPES, 100 mM NaCl, 0.1% Triton X-100, 0.5 mM DTT, pH 7.5). The assay cocktail was then incubated for 1 h at room temperature and distributed using a WellMate instrument (Matrix). Compounds to be screened were added to assay plates from DMSO stock solutions by pin transfer using 50SS pins (V&P Scientific). The assay mixture was incubated for 1 h at room temperature prior to measuring the TR-FRET signal with a PHERAstar FS plate reader (BMG Labtech) equipped with excitation modules at 337 nm and emissions at 490 and 520 nm. We set the integration start to 100 µs and the integration time to 200 µs. The number of flashes was set to 100. The ratio of 520:490 was used as TR-FRET signal in calculations. Assay endpoints were normalized from 0% (DMSO only) to 100% inhibition (unlabeled competitor peptide) for hit selection and curve fitting. All compounds were tested in triplicate or more.

### **Liver Microsomal Stability**

We mixed 0.633 mL of mouse liver microsome (20 mg/mL, female CD9 mice, Fisher Scientific, #NC9567486) with 0.051 ml of 0.5 M EDTA solution and 19.316 ml potassium phosphate buffer (0.1 M, pH 7.4, 37°C) to produce 20 ml of liver microsome solution. One part 10 mM DMSO compound stock was mixed with 4 parts acetonitrile to make 2 mM diluted compound stock in DMSO and acetonitrile. We added 29.1 µL diluted compound stock to 2.3 mL liver microsomal solution and ran the mixture through a vortex to make final microsomal solution with 0.8 µM compound. We dispensed 180 µL of the mixed solutions into a 96-well storage plate (pION Inc., MA, #110323). Five time points (0-4 hr) were taken for each microsome assay. For the 0 h time point, 450 µL pre-cooled (4 °C) internal standard (5 µM caffeine in methanol) was added to the deep wells before the reaction started. For other time points, 1.25 ml of microsome assay solution A (Fisher Scientific, #NC9255727) was combined with 0.25 ml of solution B (Fisher Scientific, #NC9016235) in 3.5 ml of potassium phosphate buffer (0.1 M, pH 7.4). We added 45

 $\mu$ L of this A+B solution to each of the 96 wells in the storage or reaction plate. The reaction plate was then sealed and incubated at 37 °C and shaken at a speed of 60 rpm. At 0.5, 1, 2, and 4 h, we added 450  $\mu$ L of pre-cooled internal standard (4  $\mu$ g/ml caffeine in methanol) to the respective wells in the reaction plate. The liquid was then transferred to a quenched plate. The quenched plate was centrifuged (Eppendorf, model 5810R) at 4000 rpm for 20 minutes at 4 °C. We transferred 200  $\mu$ L of supernatant to a 96-well plate and analyzed using UPLC-MS (Waters Inc.). Selected ion recording (SIR) was used to detect the compounds and internal standard. The log peak area ratio (compound peak area / internal standard peak area) was plotted against time and the slope was used to calculate the elimination rate constant [k = (-2.303) \* slope]. The half-life (h) was calculated as t (1/2) = 0.693 / k. All compounds were tested in triplicate.

#### Characterization of key compounds and intermediates

All moisture-sensitive reactions were performed using syringe-septum techniques under an atmosphere of dry N<sub>2</sub> unless otherwise noted. Prior to use, all glassware was dried in an oven at 120° C for at least 6 h or flame-dried under an atmosphere of dry nitrogen. Methylene chloride and acetonitrile were dried using an aluminum oxide column. Deuterated chloroform was stored over anhydrous potassium carbonate. Reactions were monitored by TLC analysis (pre-coated silica gel 60  $F_{254}$  plates, 250 µm layer thickness) and visualized using an ultraviolet lamp (254 nm) or by staining with either Vaughn's reagent (4.8 g of (NH<sub>4</sub>)<sub>6</sub>Mo<sub>7</sub>O<sub>24</sub>·4H<sub>2</sub>O and 0.2 g of Ce(SO<sub>4</sub>)<sub>2</sub> in 100 mL of a 3.5 N H<sub>2</sub>SO<sub>4</sub>) or a potassium permanganate solution (1.5 g of KMnO<sub>4</sub> and 1.5 g of K<sub>2</sub>CO<sub>3</sub> in 100 mL of a 0.1% NaOH solution). Unless otherwise specified, commercially available reagents were used as received. Flash column chromatography was performed using a Biotage Isolera One and Biotage KP-SIL SNAP cartridges. Melting points were acquired on Buchi Melting Point B-545. All NMR data was collected at room temperature in CDCl<sub>3</sub> or (CD<sub>3</sub>)<sub>2</sub>SO on a 400 or 500 MHz Bruker instrument. Chemical shifts ( $\delta$ ) are reported in parts per million (ppm) with

internal CHCl<sub>3</sub> ( $\delta$  7.26 ppm for <sup>1</sup>H and 77.00 ppm for <sup>13</sup>C), internal DMSO ( $\delta$  2.50 ppm for <sup>1</sup>H and 39.52 ppm for <sup>13</sup>C), or internal TMS ( $\delta$  0.0 ppm for <sup>1</sup>H and 0.0 ppm for <sup>13</sup>C) as the references. <sup>1</sup>H NMR data are reported as follows: chemical shift; multiplicity (s = singlet, bs = broad singlet, d = doublet, t = triplet, q = quartet, p = pentet, sext = sextet, sep = septet, m= multiplet, dd = doublet of doublets, dt = doublet of triplets, td = triplet of doublets, qd = quartet of doublets); coupling constant(s) (*J*) in Hertz (Hz); and integration. Purity was assessed by LC/MS/UV/ELSD using a Waters Acquity UPLC-MS with the purity being assigned as the average determined by UV/ELSD. All compounds were confirmed to  $\geq$  95% purity. Compounds that proved critical to our SAR analysis were further characterized using 1H NMR and HRMS.

N-benzyl-1-(pentan-2-yl)piperidin-4-amine (15).

We added acetic acid (2.11 mL, 36.9 mmol, 1.2 equiv) to a stirred solution of  $14^{42}$  (5.20 g, 30.7 mmol, 1 equiv) and benzylamine (3.36 ml, 30.7 mmol, 1 equiv) in CH<sub>2</sub>Cl<sub>2</sub> (50 mL). The resulting cloudy mixture was stirred at room temperature for 1 h and sodium triacetoxyborohydride (8.46 g, 39.9 mmol, 1.3 equiv) was added portion-wise over 10 min. The resulting heterogeneous mixture was stirred at room temperature overnight (ca. 16 h), quenched with a saturated aqueous solution of 1M sodium hydroxide, extracted with EtOAc (x2), dried (MgSO<sub>4</sub>), filtered, and concentrated under reduced pressure to give 8.0 g (100% yield) of the desired product (**15**) as a pale yellow oil. <sup>1</sup>H NMR (500 MHz, Chloroform-*d*)  $\delta$  7.36 – 7.28 (m, 4H), 7.26 – 7.17 (m, 1H), 3.81 (s, 2H), 2.81 – 2.76 (m, 2H), 2.59 (sext, *J* = 6.6 Hz, 1H), 2.51 – 2.46 (m, *J* = 1H), 2.32 (t, *J* = 11.2 Hz, 1H), 2.19 (t, *J* = 11.3 Hz, 1H), 1.98 – 1.83 (m, 2H), 1.70 – 1.22 (m, 6H), 0.96 (d, *J* = 6.5 Hz, 3H), 0.90 (t, *J* = 7.1 Hz, 3H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>)  $\delta$  140.8, 128.4, 128.0, 126.8, 59.0, 54.4, 50.7, 48.5, 45.7, 35.7, 33.1, 32.9, 20.2, 14.3, 14.1. HRMS (ESI+) m/z calcd for C<sub>17</sub>H<sub>29</sub>N<sub>2</sub> [M+H]<sup>+</sup>, 261.2331, found 261.2327.

tert-butyl 4-(benzylamino)piperidine-1-carboxylate (17).

We added acetic acid (2.76 mL, 48.2 mmol, 1.2 equiv) to a stirred solution of 1-Boc-4piperidone (8.00 g, 40.2 mmol, 1 equiv) and benzylamine (4.39 mL, 40.2 mmol, 1 equiv) in dry CH<sub>2</sub>Cl<sub>2</sub> (150 mL). The resulting cloudy mixture was stirred at room temperature for 1 h and sodium triacetoxyborohydride (11.4 g, 60.3 mmol, 1.5 equiv) was added portion-wise over 30 minutes. The resulting heterogeneous mixture was stirred at room temperature overnight (ca. 16 h), quenched with a saturated aqueous solution of NaHCO<sub>3</sub>, extracted with EtOAc (x2), dried (MgSO<sub>4</sub>), filtered, and concentrated under reduced pressure. The crude mixture was purified by chromatography on SiO<sub>2</sub> (MeOH/CH<sub>2</sub>Cl<sub>2</sub>, 2% to 15%) to give 11.4 g (98% yield) of the desired product of a colorless oil. <sup>1</sup>H NMR (500 MHz, Chloroform-*d*)  $\delta$  7.37 – 7.32 (m, 4H), 7.30 – 7.23 (m, 1H), 4.20 – 3.90 (m, 3H), 3.85 (s, 2H), 2.85 – 2.75 (m, 2H), 2.72 – 2.67 (m, 1H), 1.89 (d, *J* = 12.8 Hz, 2H), 1.47 (s, 9H), 1.40 – 1.32 (m, 2H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>)  $\delta$  154.7, 139.3, 128.5, 128.2, 127.2, 79.4, 54.1, 50.4, 42.6, 42.1, 31.9, 28.4. HRMS (ESI+) *m/z* calcd for C<sub>17</sub>H<sub>27</sub>N<sub>2</sub>O<sub>2</sub> [M+H]<sup>+</sup>, 291.2073, found 291.2067

tert-butyl 4-(1-benzyl-3-(3-fluoro-5-(trifluoromethyl)phenyl)ureido)piperidine-1-carboxylate (18).

To a stirred solution of **17** (2.90 g, 9.99 mmol, 1 equiv) in  $CH_2Cl_2$  (50 mL), we added 1isocyanato-3-(trifluoromethyl)benzene (1.44 mL, 9.99 mmol, 1.1 equiv). The reaction mixture was stirred at room temperature overnight (ca. 16 h), diluted with EtOAc, washed with a saturated aqueous solution of NaHCO<sub>3</sub>, brine, dried (MgSO<sub>4</sub>), filtered, and concentrated under reduced pressure to give a pale yellow liquid. The crude mixture was purified by chromatography on SiO<sub>2</sub> (MeOH/CH<sub>2</sub>Cl<sub>2</sub>, 1% to 10%) to give 4.8 g (97% yield) of the desired product **18** as a white solid. <sup>1</sup>H NMR (400 MHz, Chloroform-*d*)  $\delta$  7.49 – 7.40 (m, 2H), 7.39 – 7.21 (m, 4H), 7.11 (s, 1H), 6.90

(d, J = 8.1 Hz, 1H), 6.62 (s, 1H), 4.60 – 4.52 (m, 1H), 4.48 (s, 2H), 4.36 – 4.01 (m, 2H), 2.90 – 2.65 (m, 2H), 1.79 (d, J = 12.3 Hz, 2H), 1.66 – 1.50 (q, J = 12.3 Hz, 2H), 1.44 (s, 9H). <sup>13</sup>C NMR (101 MHz, Chloroform-*d*)  $\delta$  162.6 (d, J = 246.4 Hz), 155.0, 154.5, 141.4 (d, J = 11.3 Hz), 132.2 (qd, J = 33.5, 9.4 Hz), 129.4, 128.2, 126.0, 123.1 (q, J = 273.5 Hz), 111.7, 109.9 (d, J = 26.2 Hz), 106.7 (d, J = 25.0 Hz), 79.8, 53.0, 46.2, 43.2, 30.0, 28.4. HRMS (ESI-) *m/z* calcd for C<sub>25</sub>H<sub>28</sub>F<sub>4</sub>N<sub>3</sub>O<sub>3</sub> [M-H]<sup>-</sup>, 494.2067, found 494.2058.

**General reductive amination procedure.**<sup>58</sup> To a stirred solution of 1-benzyl-3-(3-fluoro-5-(trifluoromethyl)phenyl)-1-(piperidin-4-yl)urea (0.040 g, 0.101 mmol, 1 equiv) in tetrahydrofuran (1 ml), we added the aldehyde or ketone (0.202 mmol, 2 equiv) and dibutyltin (IV) chloride (1.53 mg, 0.005 mmol, 0.05 equiv). After stirring the heterogeneous mixture for 5 minutes at room temperature, we added phenylsilane (0.025 ml, 0.202 mmol, 2 equiv). The resulting solution was stirred at room temperature overnight (ca. 16 h). For some more sterically encumbered ketones, we observed less than 20% conversion after overnight reaction. For these ketones, we added an extra 3-4 equiv of ketone and 2 equiv of phenylsilane and the reaction was stirred at room temperature for an additional 24 h. After the starting material was completely consumed, the crude mixture was diluted with DMSO, filtered through a 0.45 micron filter, and subjected to HPLC chromatography.

**General isocyanate addition.** To a stirred solution of 1-benzylpiperidin-4-amine (0.250 g, 1.314 mmol, 1.2 equiv) in  $CH_2Cl_2$  (6 mL), we added 1-isocyanato-3-(trifluoromethyl)benzene (1.53 mL, 1.10 mmol, 1 equiv) and N,N-diisopropylethylamine (0.286 mL, 1.64 mmol, 1.5 equiv). The resulting mixture was stirred at room temperature overnight (ca. 16 h), concentrated under reduced pressure, and purified by chromatography on SiO<sub>2</sub>.

**General CDI-mediated isocyanate addition.** We added carbonyldiimidazole (0.026 g, 0.158 mmol, 1.3 equiv) to a stirred solution of aniline (0.146 mmol, 1.2 equiv) in tetrahydrofuran (1 ml). The mixture was stirred at room temperature for 3 h, followed by the addition of N-benzyl-1butylpiperidin-4-amine (**20**) (0.030 g, 0.122 mmol, 1 equiv). The resulting solution was stirred at room temperature overnight (ca. 16 h). The crude mixture was diluted with DMSO, filtered through a 0.45 micron filter, and directly subjected to HPLC chromatography.

#### Reproduction of characterization from previously reported key compounds.

1-benzyl-1-(1-(pentan-2-yl)piperidin-4-yl)-3-(3-(trifluoromethyl)phenyl)urea (7).<sup>42</sup>

Note: characterization was previously reported<sup>42</sup> but is reproduced below for convenience: <sup>1</sup>H NMR (500 MHz, Chloroform-*d*)  $\delta$  7.57 (s, 1H), 7.42 – 7.36 (m, 2H), 7.34-7.30 (m, 3H), 7.29 – 7.17 (m, 4H), 6.50 (s, 1H), 4.53 (s, 2H), 4.37 (tt, *J* = 12.1, 4.2 Hz, 1H), 2.84-2.80 (m, 2H), 2.57 (sext, *J* = 7.0 Hz, 1H), 2.42 (td, *J* = 11.6, 2.5 Hz, 1H), 2.27 (td, *J* = 11.6, 2.3 Hz, 1H), 1.83 – 1.76 (m, 2H), 1.69 (dqd, *J* = 24.1, 12.0, 3.8 Hz, 2H), 1.47 (dq, *J* = 12.5, 5.2 Hz, 1H), 1.41 – 1.13 (m, 3H), 0.95 (d, *J* = 6.6 Hz, 3H), 0.89 (t, *J* = 7.1 Hz, 3H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>)  $\delta$  155.4, 139.6, 137.5, 130.8 (q, *J* = 31.5 Hz), 129.1, 129.0, 127.1, 126.0, 123.9 (q, *J* = 273.4 Hz, 1C), 122.6, 119.2 (q, *J* = 3.8 Hz), 116.3 (q, *J* = 3.8 Hz), 58.8, 53.2, 49.5, 46.1, 46.0, 35.7, 30.6, 30.4, 20.1, 14.1, 14.0. *m/z* (APCl-pos) M+1 = 448.2. HRMS (ESI+) *m/z* calcd for C<sub>25</sub>H<sub>33</sub>F<sub>3</sub>N<sub>3</sub>O [M+H]<sup>+</sup>, 448.2575 found 448.2575.

1-benzyl-1-(1-butylpiperidin-4-yl)-3-(3,4-dichlorophenyl)urea. NAcM-OPT (67).42

Note: characterization was previously reported<sup>42</sup> but is reproduced below for convenience: m.p.: 118-120 °C. <sup>1</sup>H NMR (500 MHz, Chloroform-*d*)  $\delta$  7.42 – 7.39 (m, 3H), 7.36 – 7.29 (m, 3H), 7.21

(d, J = 8.7 Hz, 1H), 6.91 (d, J = 8.7 Hz, 1H), 6.27 (s, 1H), 4.49 (s, 2H), 4.44 – 4.38 (m, 1H), 2.99 (d, J = 11.2 Hz, 2H), 2.31 (t, J = 7.8 Hz, 2H), 2.05 (t, J = 11.7 Hz, 2H), 1.85 – 1.65 (m, 4H), 1.44 (p, J = 7.5 Hz, 2H), 1.30 (sext, J = 7.4 Hz, 2H), 0.90 (t, J = 7.4 Hz, 3H). <sup>13</sup>C NMR (126 MHz, Chloroform-*d*)  $\delta$  155.3, 138.6, 137.4, 132.4, 130.1, 129.3, 128.0, 126.1, 125.9, 121.2, 118.8, 58.4, 53.1, 52.9, 46.1, 30.1, 29.4, 20.8, 14.0. HRMS (ESI+) *m/z* calcd for C<sub>23</sub>H<sub>30</sub>Cl<sub>2</sub>N<sub>3</sub>O [M+H]<sup>+</sup> 434.1766, found 434.1761.

#### **Ancillary Information**

#### **Supporting Information:**

Characterization details for the other synthetic compounds as well as additional information regarding the biological studies are described in Supporting Information.

#### **Corresponding Author Information**

\*E-mail: Kip.guy@uky.edu. Phone: 901-595-5714. Fax: 901-595-5715

#### **Present/Current Author Addresses:**

Brenda A. Schulman: Department of Molecular Machines and Signaling, Max Planck Institute of Biochemistry, Martinsried, Germany

Jared T. Hammill, Yizhe Chen, Ho Shin Kim, and R. Kiplin Guy: Department of Pharmaceutical Sciences, University of Kentucky, Lexington, KY 40508

#### **Author Contributions:**

All authors contributed to specific parts of the manuscript. J.T.H and R.K.G. assume responsibility for the manuscript in its entirety. All authors have given approval to the final version of the manuscript.

# Acknowledgments:

American Lebanese Syrian Associated Charities. We acknowledge the High Throughput Biosciences Center, Medicinal Chemistry Center, Compound Management, and High Throughput Analytical Chemistry Centers in Chemical Biology and Therapeutics; Hartwell Center, and Veterinary pathology cores of St. Jude Children's Research Hospital for use of their personnel and facilities. This study was funded through B.A.S., HHMI, and NIH R37GM069530, P30CA021765; J.T.H., NIH F32GM113310; American Syrian Lebanese Associated Charities, and St Jude Children's Research Hospital.

# Abbreviations Used:

DCN1, defective in cullin neddylation 1; UBE2M, NEDD8-conjugating enzyme Ubc12; SCC, Squamous cell carcinoma; CRL, cullin ring ligases; NEDD8, Neural Precursor Cell Expressed, Developmentally Down-Regulated 8; SAR, structure-activity relationship; SPR, structure-property relationship; TR-FRET, time-resolved fluorescence resonance energy transfer; HTS, high-throughput screen; t-Bu, *tert*-butyl; NAE, NEDD8-activating enzyme; RBX1, Ring-Box 1, E3 Ubiquitin Protein Ligase; CUL1, cullin 1; AF, AlexaFluor 488; IV, intravenous; PO, *per os* (by mouth); CL<sub>int</sub>, intrinsic clearence; C<sub>max</sub>, maximum achieved concentration; t<sub>(1/2)</sub>, half-life (time taken for the concentration of analyte to fall to half its original value); AUC<sub>last</sub>, area under the plasma concentration-time curve from time zero to time of last measurable concentration.

1 2 3 4		<u>References</u>
5 6	1.	Hammill, J. T.; Scott, D. C.; Min, J.; Connelly, M.; Holbrook, G.; Zhu, F.; Matheny, A.;
/ 8		Yang, L.; Singh, B.; Schulman, B. A.; Guy, R. K. Piperidinyl ureas chemically control
9 10 11		defective in cullin neddylation 1 (DCN1)-mediated cullin neddylation. J. Med. Chem. 2018,
12 13		citation to be provided at time of publication.
14 15	2.	Zhang, J.; Wu, P.; Hu, Y. Clinical and marketed proteasome inhibitors for cancer
16 17		treatment. Curr. Med. Chem. 2013, 20 (20), 2537-2551.
18 19	3.	Lydeard, J. R.; Harper, J. W. Inhibitors for E3 ubiquitin ligases. Nat. Biotechnol. 2010, 28
20 21		(7), 682-684.
22 23	4.	Ciechanover, A. Intracellular protein degradation: from a vague idea through the lysosome
24 25		and the ubiquitin-proteasome system and onto human diseases and drug targeting.
26 27		Bioorg. Med. Chem. <b>2013</b> , 21 (12), 3400-3410.
28 29	5.	Bassermann, F.; Eichner, R.; Pagano, M. The ubiquitin proteasome system - implications
30 31		for cell cycle control and the targeted treatment of cancer. <i>Biochim. Biophys. Acta.</i> 2014.
32 33		<i>1843</i> (1), 150-162.
34 35 26	6.	Soucy, T. A.: Smith, P. G.: Milhollen, M. A.: Berger, A. J.: Gavin, J. M.: Adhikari, S.:
30 37 38		Brownell J. F. Burke, K. F. Cardin, D. P. Critchlev, S. Cullis, C. A. Doucette, A.
39 40		Garnsey, J. J. Gaulin, J. J. Gershman, R. F. Lublinsky, A. R. McDonald, A. Mizutani,
40 41 42		H: Narayanan II: Olbaya E. I: Peluso S: Rezaei M: Sintchak M. D: Talreia T:
43 44		The management of the second s
45 46		Di Cleibarra C. E. Delfa M. Balar, J. B. Langston, C. D. An inhibitar of NEDDa
47 48		R.; Claiporne, C. F.; Rolfe, M.; Bolen, J. B.; Langston, S. P. An Inhibitor of NEDD8-
49 50	_	activating enzyme as a new approach to treat cancer. <i>Nature</i> <b>2009</b> , 458 (7239), 732-736.
51 52	7.	Sarkaria, I.; P, O. c.; Talbot, S. G.; Reddy, P. G.; Ngai, I.; Maghami, E.; Patel, K. N.; Lee,
53 54		B.; Yonekawa, Y.; Dudas, M.; Kaufman, A.; Ryan, R.; Ghossein, R.; Rao, P. H.; Stoffel,
55 56		A.; Ramanathan, Y.; Singh, B. Squamous cell carcinoma related oncogene/DCUN1D1 is
57 58		

highly conserved and activated by amplification in squamous cell carcinomas. *Cancer Res.* **2006**, *66* (19), 9437-9444.

- Estilo, C. L.; P, O. C.; Ngai, I.; Patel, S. G.; Reddy, P. G.; Dao, S.; Shaha, A. R.; Kraus, D. H.; Boyle, J. O.; Wong, R. J.; Pfister, D. G.; Huryn, J. M.; Zlotolow, I. M.; Shah, J. P.; Singh, B. The role of novel oncogenes squamous cell carcinoma-related oncogene and phosphatidylinositol 3-kinase p110alpha in squamous cell carcinoma of the oral tongue. *Clin. Cancer Res.* 2003, *9* (6), 2300-2306.
- P, O. c.; Sarkaria, I.; Talbot, S. G.; Reddy, P.; Dao, S.; Ngai, I.; Shaha, A.; Kraus, D.; Shah, J.; Rusch, V.; Ramanathan, Y.; Singh, B. SCCRO (DCUN1D1) induces extracellular matrix invasion by activating matrix metalloproteinase 2. *Clin. Cancer Res.* 2008, *14* (21), 6780-6789.
- Talbot, S. G.; P, O. c.; Sarkaria, I. S.; Ghossein, R.; Reddy, P.; Ngai, I.; Cordeiro, C. N.; Wong, R. J.; Kris, M. G.; Rusch, V. W.; Singh, B. Squamous cell carcinoma related oncogene regulates angiogenesis through vascular endothelial growth factor-A. *Ann. Surg. Oncol.* 2004, *11* (5), 530-534.
- 11. Huang, G.; Singh, B. Coamplification and cooperation: toward identifying biologically relevant oncogenes. *Clin. Cancer Res.* **2013**, *19* (20), 5549-5551.
- Wang, J.; Qian, J.; Hoeksema, M. D.; Zou, Y.; Espinosa, A. V.; Rahman, S. M.; Zhang, B.; Massion, P. P. Integrative genomics analysis identifies candidate drivers at 3q26-29 amplicon in squamous cell carcinoma of the lung. *Clin. Cancer Res.* 2013, *19* (20), 5580-5590.
- Chen, Y.; McGee, J.; Chen, X.; Doman, T. N.; Gong, X.; Zhang, Y.; Hamm, N.; Ma, X.; Higgs, R. E.; Bhagwat, S. V.; Buchanan, S.; Peng, S. B.; Staschke, K. A.; Yadav, V.; Yue, Y.; Kouros-Mehr, H. Identification of druggable cancer driver genes amplified across TCGA datasets. *PloS one* **2014**, *9* (5), e98293.

2		
3 4	14.	Hershko, A.; Ciechanover, A. The ubiquitin system. Annu. Rev. Biochem. 1998, 67, 425-
5		479.
7 8	15.	Scott, D. C.; Sviderskiy, V. O.; Monda, J. K.; Lydeard, J. R.; Cho, S. E.; Harper, J. W.;
9 10		Schulman, B. A. Structure of a RING E3 trapped in action reveals ligation mechanism for
11 12		the ubiquitin-like protein NEDD8. Cell 2014, 157 (7), 1671-1684.
13 14	16.	Scott, D. C.; Monda, J. K.; Bennett, E. J.; Harper, J. W.; Schulman, B. A. N-terminal
15 16		acetylation acts as an avidity enhancer within an interconnected multiprotein complex.
17 18		Science <b>2011</b> , 334 (6056), 674-678.
19 20	17.	Duda, D. M.; Borg, L. A.; Scott, D. C.; Hunt, H. W.; Hammel, M.; Schulman, B. A. Structural
21 22		insights into NEDD8 activation of cullin-RING ligases: conformational control of
23 24		conjugation. <i>Cell</i> <b>2008</b> , <i>134</i> (6), 995-1006.
25 26	18.	Enchev, R. I.; Schulman, B. A.; Peter, M. Protein neddylation: beyond cullin-RING ligases.
27 28 20		Nat. Rev. Mol. Cell Biol. <b>2015,</b> 16 (1), 30-44.
29 30 21	19.	Lydeard, J. R.: Schulman, B. A.: Harper, J. W. Building and remodelling Cullin-RING E3
32		ubiquitin ligases. <i>FMBO Rep.</i> <b>2013</b> . <i>14</i> (12), 1050-1061.
33 34 35	20	Deshaies R. L. Joazeiro, C. A. RING domain F3 ubiquitin ligases. Annu. Rev. Biochem
36 37	20.	<b>2000</b> 78 300-434
38 39	21	Potrocki M. D.: Dochoico, P. J. Eurotian and regulation of cullin PINC ubiquitin ligance.
40 41	21.	Net Day Mal Call Dial 2005 6(1) 0.20
42		Nal. Rev. Mol. Cell Biol. 2003, 8 (1), 9-20.
44	22.	Lu, A.; Pfeffer, S. R. A CULLINary ride across the secretory pathway: more than just
45 46		secretion. Trends Cell Biol. 2014, 24 (7), 389-399.
47 48	23.	Cui, D.; Xiong, X.; Zhao, Y. Cullin-RING ligases in regulation of autophagy. Cell Div. 2016,
49 50		11, 8-22.
51 52	24.	Bielskiene, K.; Bagdoniene, L.; Mozuraitiene, J.; Kazbariene, B.; Janulionis, E. E3
53 54		ubiquitin ligases as drug targets and prognostic biomarkers in melanoma. Medicina
55 56		(Kaunas) <b>2015,</b> <i>51</i> (1), 1-9.
57 58		
59 60		ACS Paragon Plus Environment

Bulatov, E.; Ciulli, A. Targeting Cullin-RING E3 ubiquitin ligases for drug discovery:

structure, assembly and small-molecule modulation. *Biochem. J.* 2015, 467 (3), 365-386. 26. Huang, X.: Dixit, V. M. Drugging the undruggables: exploring the ubiguitin system for drug development. Cell Res. 2016, 26 (4), 484-498. 27. Weathington, N. M.; Mallampalli, R. K. Emerging therapies targeting the ubiquitin proteasome system in cancer. J. Clin. Invest. 2014, 124 (1), 6-12. 28. Rulina, A. V.; Mittler, F.; Obeid, P.; Gerbaud, S.; Guyon, L.; Sulpice, E.; Kermarrec, F.; Assard, N.; Dolega, M. E.; Gidrol, X.; Balakirev, M. Y. Distinct outcomes of CRL-Nedd8 pathway inhibition reveal cancer cell plasticity. Cell Death Dis. 2016, 7 (12), e2505. 29. Abidi, N.; Xirodimas, D. P. Regulation of cancer-related pathways by protein NEDDylation and strategies for the use of NEDD8 inhibitors in the clinic. Endocr. Relat. Cancer 2015, 22 (1), T55-70. 30. Tanaka, T.: Nakatani, T.: Kamitani, T. Inhibition of NEDD8-conjugation pathway by novel molecules: potential approaches to anticancer therapy. Mol. Oncol. 2012, 6 (3), 267-275. Soucy, T. A.; Smith, P. G.; Rolfe, M. Targeting NEDD8-activated cullin-RING ligases for 31. the treatment of cancer. Clin. Cancer Res. 2009, 15 (12), 3912-3916. Milhollen, M. A.; Narayanan, U.; Soucy, T. A.; Veiby, P. O.; Smith, P. G.; Amidon, B. 32. Inhibition of NEDD8-activating enzyme induces rereplication and apoptosis in human tumor cells consistent with deregulating CDT1 turnover. Cancer Res. 2011, 71 (8), 3042-3051. 33. Milhollen, M. A.; Traore, T.; Adams-Duffy, J.; Thomas, M. P.; Berger, A. J.; Dang, L.; Dick, L. R.; Garnsey, J. J.; Koenig, E.; Langston, S. P.; Manfredi, M.; Narayanan, U.; Rolfe, M.; Staudt, L. M.; Soucy, T. A.; Yu, J.; Zhang, J.; Bolen, J. B.; Smith, P. G. MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-{kappa}B-dependent lymphoma. Blood 2010, 116 (9), 1515-1523.

25.

59

60

2		
3 4	34.	Brownell, J. E.; Sintchak, M. D.; Gavin, J. M.; Liao, H.; Bruzzese, F. J.; Bump, N. J.; Soucy,
5 6		T. A.; Milhollen, M. A.; Yang, X.; Burkhardt, A. L.; Ma, J.; Loke, H. K.; Lingaraj, T.; Wu, D.;
7 8		Hamman, K. B.; Spelman, J. J.; Cullis, C. A.; Langston, S. P.; Vyskocil, S.; Sells, T. B.;
9 10		Mallender, W. D.; Visiers, I.; Li, P.; Claiborne, C. F.; Rolfe, M.; Bolen, J. B.; Dick, L. R.
11 12		Substrate-assisted inhibition of ubiquitin-like protein-activating enzymes: the NEDD8 E1
13 14		inhibitor MLN4924 forms a NEDD8-AMP mimetic in situ. <i>Mol. Cell</i> <b>2010</b> , <i>37</i> (1), 102-111.
15 16	35.	Lu, P.; Liu, X.; Yuan, X.; He, M.; Wang, Y.; Zhang, Q.; Ouyang, P. K. Discovery of a novel
17 18		NEDD8 activating enzyme inhibitor with piperidin-4-amine scaffold by structure-based
19 20		virtual screening. ACS Chem. Biol. <b>2016.</b> <i>11</i> (7), 1901-1907.
21 22	36	Leung C. H. Chan, D. S. Yang H. Abagyan, R. Lee, S. M. Zhu, G. Y. Fong, W. F.
23 24	00.	Ma D L A natural product-like inhibitor of NEDD8-activating enzyme. <i>Chem. Commun.</i>
25 26		
27 28	07	<b>2011,</b> 47 (9), 2511-2513.
29 30	37.	Zhong, H. J.; Ma, V. P.; Cheng, Z.; Chan, D. S.; He, H. Z.; Leung, K. H.; Ma, D. L.; Leung,
31 32		C. H. Discovery of a natural product inhibitor targeting protein neddylation by structure-
33 34		based virtual screening. Biochimie 2012, 94 (11), 2457-2460.
35	38.	Zhang, S.; Tan, J.; Lai, Z.; Li, Y.; Pang, J.; Xiao, J.; Huang, Z.; Zhang, Y.; Ji, H.; Lai, Y.
37 38		Effective virtual screening strategy toward covalent ligands: identification of novel NEDD8-
39 40		activating enzyme inhibitors. J. Chem. Inf. Model. 2014, 54 (6), 1785-1797.
41	39.	Zhong, H. J.; Wang, W.; Kang, T. S.; Yan, H.; Yang, Y.; Xu, L.; Wang, Y.; Ma, D. L.; Leung,
43 44		C. H. A Rhodium(III) complex as an inhibitor of neural precursor cell expressed,
45		developmentally down-regulated 8-activating enzyme with in vivo activity against
47		inflammatory bowel disease. J. Med. Chem. 2017, 60 (1), 497-503.
49	40.	Zhong, H. J.; Yang, H.; Chan, D. S.; Leung, C. H.; Wang, H. M.; Ma, D. L. A metal-based
51 52		inhibitor of NEDD8-activating enzyme. <i>PloS one</i> <b>2012.</b> 7 (11), e49574.
53 54	41	Schlierf A Altmann E Quancard J Jefferson A B Assenberg R Renatus M
55 56		Iones M : Hassienen II : Schaefer M : Kiffe M : Weiss A : Wiesmann C : Sedrani R :
57 58		

Eder, J.; Martoglio, B. Targeted inhibition of the COP9 signalosome for treatment of cancer. *Nat. Commun.* **2016**, *7*, 13166.

- Scott, D. C.; Hammill, J. T.; Min, J.; Rhee, D. Y.; Connelly, M.; Sviderskiy, V. O.; Bhasin, D.; Chen, Y.; Ong, S. S.; Chai, S. C.; Goktug, A. N.; Huang, G.; Monda, J. K.; Low, J.; Kim, H. S.; Paulo, J. A.; Cannon, J. R.; Shelat, A. A.; Chen, T.; Kelsall, I. R.; Alpi, A. F.; Pagala, V.; Wang, X.; Peng, J.; Singh, B.; Harper, J. W.; Schulman, B. A.; Guy, R. K. Blocking an N-terminal acetylation-dependent protein interaction inhibits an E3 ligase. *Nat. Chem. Biol.* 2017, *13* (8), 850-857.
- Zhou, H.; Lu, J.; Liu, L.; Bernard, D.; Yang, C. Y.; Fernandez-Salas, E.; Chinnaswamy, K.; Layton, S.; Stuckey, J.; Yu, Q.; Zhou, W.; Pan, Z.; Sun, Y.; Wang, S. A potent smallmolecule inhibitor of the DCN1-UBC12 interaction that selectively blocks cullin 3 neddylation. *Nat. Commun.* 2017, 8 (1), 1150.
- Zhou, H.; Zhou, W.; Zhou, B.; Liu, L.; Chern, T. R.; Chinnaswamy, K.; Lu, J.; Bernard, D.;
  Yang, C. Y.; Li, S.; Wang, M.; Stuckey, J.; Sun, Y.; Wang, S. High-affinity peptidomimetic inhibitors of the DCN1-UBC12 protein-protein interaction. *J. Med. Chem.* 2018, *61* (5), 1934-1950.
- Broderick, S. R.; Golas, B. J.; Pham, D.; Towe, C. W.; Talbot, S. G.; Kaufman, A.; Bains, S.; Huryn, L. A.; Yonekawa, Y.; Carlson, D.; Hambardzumyan, D.; Ramanathan, Y.; Singh,
  B. SCCRO promotes glioma formation and malignant progression in mice. *Neoplasia* 2010, *12* (6), 476-484.
- Yoo, J.; Lee, S. H.; Lym, K. I.; Park, S. Y.; Yang, S. H.; Yoo, C. Y.; Jung, J. H.; Kang, S. J.; Kang, C. S. Immunohistochemical expression of DCUN1D1 in non-small cell lung carcinoma: its relation to brain metastasis. *Cancer Res. Treat.* **2012**, *44* (1), 57-62.
- 47. Hansch, C.; Fujita, T. p-σ-π Analysis. A Method for the correlation of biological activity and chemical structure. *J. Am. Chem. Soc.* **1964**, *86* (8), 1616-1626.

2		
3 4	48.	Hansch, C.; Leo, A.; Taft, R. W. A survey of Hammett substituent constants and resonance
5 6		and field parameters. Chem. Rev. 1991, 91 (2), 165-195.
7 8	49.	Hammett, L. P. The effect of structure upon the reactions of organic compounds. benzene
9 10		derivatives. J. Am. Chem. Soc. 1937, 59 (1), 96-103.
11 12	50.	Hansch, C.; Maloney, P. P.; Fujita, T.; Muir, R. M. Correlation of biological activity of
13 14		phenoxyacetic acids with hammett substituent constants and partition coefficients. Nature
15 16		<b>1962,</b> <i>194</i> (4824), 178-180.
17 18	51.	Cherkasov, A.; Muratov, E. N.; Fourches, D.; Varnek, A.; Baskin, II; Cronin, M.; Dearden,
19 20		J.; Gramatica, P.; Martin, Y. C.; Todeschini, R.; Consonni, V.; Kuz'min, V. E.; Cramer, R.;
21 22 22		Benigni, R.; Yang, C.; Rathman, J.; Terfloth, L.; Gasteiger, J.; Richard, A.; Tropsha, A.
23 24 25		QSAR modeling: where have you been? where are you going to? J. Med. Chem. 2014,
26 27		57 (12), 4977-5010.
28 29	52.	Sun, H.; Scott, D. O. Metabolism of 4-aminopiperidine drugs by cytochrome P450s:
30 31		molecular and quantum mechanical insights into drug design. ACS Med. Chem. Lett.
32 33		<b>2011,</b> <i>2</i> (8), 638-643.
34 35	53.	Rydberg, P.; Ryde, U.; Olsen, L. Prediction of activation energies for aromatic oxidation
36 37		by cytochrome P450. <i>J. Phys. Chem. A</i> <b>2008,</b> <i>112</i> (50), 13058-13065.
38 39	54.	Carling, R. W.; Moore, K. W.; Moyes, C. R.; Jones, E. A.; Bonner, K.; Emms, F.; Marwood,
40 41		R.; Patel, S.; Patel, S.; Fletcher, A. E.; Beer, M.; Sohal, B.; Pike, A.; Leeson, P. D. 1-(3-
42 43		Cyanobenzylpiperidin-4-yl)-5-methyl-4-phenyl-1, 3-dihydroimidazol-2-one: a selective
44 45		high-affinity antagonist for the human dopamine D(4) receptor with excellent selectivity
40 47 48		over ion channels. <i>J. Med. Chem.</i> <b>1999,</b> <i>4</i> 2 (14), 2706-2715.
40 49 50	55.	Archibald, J. L.; Beardsley, D. R.; Bisset, G. M.; Fairbrother, P.; Jackson, J. L.; Opalko,
50 51 52		A.; Ward, T. J. Antihypertensive ureidopiperidines. J. Med. Chem. 1980, 23 (8), 857-861.
53 54		
55		

56. McNulty, J.; Nair, J. J.; Singh, M.; Crankshaw, D. J.; Holloway, A. C. Potent and selective inhibition of human cytochrome P450 3A4 by seco-pancratistatin structural analogs. *Bioorg. Med. Chem. Lett.* **2010**, *20* (7), 2335-2339.

- 57. Seifert, K.; Buttner, A.; Rigol, S.; Eilert, N.; Wandel, E.; Giannis, A. Potent small molecule Hedgehog agonists induce VEGF expression in vitro. *Bioorg. Med. Chem.* 2012, *20* (21), 6465-6481.
- 58. Apodaca, R.; Xiao, W. Direct reductive amination of aldehydes and ketones using phenylsilane: catalysis by dibutyltin dichloride. *Org. Lett.* **2001**, *3* (11), 1745-1748.
- 59. Ritz, C.; Streibig, J. C. Bioassay Analysis Using R. J. Stat. Softw. 2005, 1 (5), 1-22.
- Purohit, V.; Basu, A. K. Mutagenicity of nitroaromatic compounds. *Chem. Res. Toxicol.* **2000**, *13* (8), 673-692.
- 61. Hallifax, D.; Houston, J. B. Evaluation of hepatic clearance prediction using in vitro data: emphasis on fraction unbound in plasma and drug ionisation using a database of 107 drugs. *J. Pharm. Sci.* **2012**, *101* (8), 2645-2652.
- Huang, G.; Kaufman, A. J.; Xu, K.; Manova, K.; Singh, B. Squamous cell carcinomarelated oncogene (SCCRO) neddylates Cul3 protein to selectively promote midbody localization and activity of Cul3KLHL21 protein complex during abscission. *J. Biol. Chem.* 2017, 292 (37), 15254-15265.

